drugset

drugset / Trial / NCT00584948

Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome

NCT00584948 ↗

Completed 94 enrolled University of California, Davis Forest Laboratories · collab National Institute on Aging (NIA) · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if memantine is effective in treating symptoms of Fragile X-associated Tremor Ataxia Syndrome.

Timeline

Start: 2007-09
Primary completion: 2012-09
Completion: 2012-09

Outcome

Mixed primary results

paper Primary outcome measures were the Behavioral Dyscontrol Scale (BDS) score and CATSYS intention tremor severity. PMID 24345444 ↗

paper intention tremor severity (mean [SD] values with memantine vs placebo: 1.05 [0.73] vs 1.89 [2.19], P = .047) PMID 24345444 ↗

paper or BDS score (16.12 [5.43] vs 15.72 [3.93], P = .727) at follow-up. PMID 24345444 ↗

Publications

Seritan AL, Nguyen DV, Mu Y, Tassone F, Bourgeois JA, Schneider A, Cogswell JB, Cook KR, Leehey MA, Grigsby J, Olichney JM, Adams PE, Legg W, Zhang L, Hagerman PJ, Hagerman RJ. Memantine for fragile X-associated tremor/ataxia syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2014 Mar;75(3):264-71. doi: 10.4088/JCP.13m08546.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Memantine	Unknown	10 mg	—

Indications